Profund Advisors LLC lowered its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 109,916 shares of the pharmaceutical company’s stock after selling 11,097 shares during the period. Vertex Pharmaceuticals accounts for 0.6% of Profund Advisors LLC’s portfolio, making the stock its 24th largest holding. Profund Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $16,472,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of VRTX. Renaissance Technologies LLC grew its holdings in shares of Vertex Pharmaceuticals by 108.2% in the 4th quarter. Renaissance Technologies LLC now owns 2,847,917 shares of the pharmaceutical company’s stock valued at $426,789,000 after buying an additional 1,479,897 shares during the period. Jennison Associates LLC lifted its position in Vertex Pharmaceuticals by 19.0% in the 3rd quarter. Jennison Associates LLC now owns 6,017,766 shares of the pharmaceutical company’s stock valued at $914,941,000 after acquiring an additional 962,644 shares in the last quarter. Point72 Asset Management L.P. lifted its position in Vertex Pharmaceuticals by 8,061.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 909,230 shares of the pharmaceutical company’s stock valued at $138,239,000 after acquiring an additional 898,089 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Vertex Pharmaceuticals by 90.1% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,203,221 shares of the pharmaceutical company’s stock valued at $180,315,000 after acquiring an additional 570,287 shares in the last quarter. Finally, Old Mutual Global Investors UK Ltd. lifted its position in Vertex Pharmaceuticals by 18.8% during the 4th quarter. Old Mutual Global Investors UK Ltd. now owns 1,428,127 shares of the pharmaceutical company’s stock worth $214,019,000 after buying an additional 226,097 shares in the last quarter. Institutional investors own 94.51% of the company’s stock.
Several equities research analysts have commented on the stock. Bank of America boosted their price target on shares of Vertex Pharmaceuticals from $180.00 to $197.00 and gave the stock a “buy” rating in a research report on Thursday, February 1st. HC Wainwright reaffirmed a “hold” rating and issued a $103.00 target price on shares of Vertex Pharmaceuticals in a report on Thursday, February 1st. BidaskClub upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. Leerink Swann reiterated an “outperform” rating and issued a $190.00 price target (up previously from $175.00) on shares of Vertex Pharmaceuticals in a research note on Thursday, February 1st. Finally, JMP Securities reiterated an “outperform” rating and issued a $211.00 price target (up previously from $200.00) on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 13th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and twenty-five have given a buy rating to the company’s stock. Vertex Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $183.96.
In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 13,750 shares of the firm’s stock in a transaction on Friday, March 9th. The shares were sold at an average price of $175.00, for a total value of $2,406,250.00. Following the completion of the sale, the executive vice president now directly owns 60,412 shares in the company, valued at $10,572,100. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Thomas Graney sold 777 shares of Vertex Pharmaceuticals stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $149.95, for a total transaction of $116,511.15. The disclosure for this sale can be found here. Insiders sold 356,966 shares of company stock valued at $57,081,624 over the last 90 days. Corporate insiders own 1.80% of the company’s stock.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded down $0.58 on Wednesday, hitting $174.38. 1,036,433 shares of the stock traded hands, compared to its average volume of 1,881,772. Vertex Pharmaceuticals Incorporated has a 52 week low of $88.90 and a 52 week high of $178.25. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.14 and a current ratio of 3.28. The firm has a market capitalization of $44,110.00, a PE ratio of 168.15, a PEG ratio of 2.52 and a beta of 1.56.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.61 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.53 by $0.08. The company had revenue of $651.63 million during the quarter, compared to analysts’ expectations of $592.49 million. Vertex Pharmaceuticals had a net margin of 10.59% and a return on equity of 11.02%. Vertex Pharmaceuticals’s revenue for the quarter was up 42.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.35 earnings per share. equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 1.67 EPS for the current fiscal year.
Vertex Pharmaceuticals declared that its Board of Directors has initiated a share repurchase plan on Wednesday, January 31st that allows the company to buyback $500.00 million in shares. This buyback authorization allows the pharmaceutical company to repurchase shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.
ILLEGAL ACTIVITY WARNING: “Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Position Decreased by Profund Advisors LLC” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://ledgergazette.com/2018/03/14/vertex-pharmaceuticals-incorporated-vrtx-stake-lessened-by-profund-advisors-llc.html.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.